Sign In
Buy ESPR
$3.14
+0 (+0%)
At Close: Jun 03, 2026
AEP, Oracle, Tesla and More Thursday Afternoon Analyst Calls
12:14pm, Thursday, 11'th Mar 2021
With the trading day halfway over, the broad markets were making yet another strong push.
Esperion: Interesting Case
10:59pm, Thursday, 25'th Feb 2021
Esperion's share price has bounced up and down during 2020 while its short interest skyrocketed.
Esperion (ESPR) Q4 Earnings Miss, Coronavirus Woes Continue
09:53am, Wednesday, 24'th Feb 2021
Esperion Therapeutics (ESPR) reports dismal fourth-quarter results as it misses estimates for earnings and sales. Sales were hurt due to COVID-19.
Esperion Therapeutics, Inc. (ESPR) CEO Timothy Mayleben on Q4 2020 Results - Earnings Call Transcript
10:27pm, Tuesday, 23'rd Feb 2021
Esperion Therapeutics, Inc. (ESPR) CEO Timothy Mayleben on Q4 2020 Results - Earnings Call Transcript
Esperion Therapeutics (ESPR) Reports Q4 Loss, Lags Revenue Estimates
06:16pm, Tuesday, 23'rd Feb 2021
Esperion Therapeutics (ESPR) delivered earnings and revenue surprises of -3.46% and -49.17%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the sto
Recap: Esperion Therapeutics Q4 Earnings
05:15pm, Tuesday, 23'rd Feb 2021
Shares of Esperion Therapeutics (NASDAQ:ESPR) decreased after-market trading after the company reported Q4 results. Quarterly Results Earnings per share were down 72.12% over the past year to ($3.89),
Esperion to Report Fourth Quarter and Full Year 2020 Financial Results February 23, 2021
08:00am, Tuesday, 09'th Feb 2021
ANN ARBOR, Mich., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced it will report fourth quarter and full year 2020 financial results after the close of the U.S. financial ma
Esperion Therapeutics: Deeply Undervalued With An Extremely High Short Interest
01:45am, Saturday, 30'th Jan 2021
Esperion is deeply undervalued company selling a new treatment in the huge and lucrative market for lowering LDL cholesterol. ESPR is highly leveraged to Covid-reopening, but unlike many industries, i
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
05:00pm, Friday, 29'th Jan 2021
ANN ARBOR, Mich., Jan. 29, 2021 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that, on January 28, 2021, the Compensation Committee of Esperion's Board of Directors granted 10 new employ
Why Novartis, BioVie, Esperion And VBI Are Moving Today
11:47am, Friday, 15'th Jan 2021
Esperion Therapeutics (NASDAQ: ESPR) shares are trading lower after Bank of America Securities downgraded the stock from Buy to Neutral and announced a price target of $35 per share. Esprit Holdings i
Esperion (ESPR) Reports Q4 Preliminary Results, Stock Down
11:17am, Thursday, 14'th Jan 2021
Esperion (ESPR) reports fourth-quarter preliminary results and provides guidance for operating expense in 2021. The company in-licenses oral PCSK9 inhibitor program.
Why Esperion Therapeutics Stock Is Falling Today
01:21pm, Wednesday, 13'th Jan 2021
The company gave a sneak peek into its fourth-quarter financial results.
– Fourth-quarter 2020 U.S. net product revenue estimated between $8.0 and $8.5 million –
Esperion to Present at the 39th Annual J.P. Morgan Healthcare Conference
08:00am, Monday, 21'st Dec 2020
ANN ARBOR, Mich., Dec. 21, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced that President and Chief Executive Officer, Tim M. Mayleben, will present at the virtual 39th Annual J.P. M
- NILEMDO ® (bempedoic acid) is the first oral, once-daily treatment approved in almost two decades to lower low-density lipoprotein cholesterol (LDL-C) for indicated patients -
